UbiVac Showcases First 'Dark Matter' Cancer Immunotherapy Data at SITC 2025
DPV-001, first cancer vaccine derived from the human dark genome, shows improved survival in head and neck cancer and reveals more than 400 new antigen targets. NATIONAL HARBOR, MD, UNITED STATES, November 10, 2025 /EINPresswire.com/ -- UbiVac, …